Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 587

Sort by

Sort Order Select

Journal Articles

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Andrew Lane, Marlise Luskin, Julia Keating, Nicole Leboeuf, Jacqueline Garcia, Shai Shimony, Rebecca Leonard, Adon Goodpaster, Theresa Nguyen, Ilene Galinsky, Ashleigh Eberly-Puleo, Naval Daver, Nitin Jain, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Anthony Selwyn Stein, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 653.

https://doi.org/10.1182/blood-2025-653

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Ghayas Issa, Hagop Kantarjian, Musa Yilmaz, Nicholas Short, Tapan Kadia, Georgina El Hajjar, Courtney DiNardo, Yesid Alvarado, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Michael Andreeff, Guillermo Garcia-Manero, Naval Daver

Blood (2025) 146 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2025-3428

Published: 2025

Journal Articles

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Vanthana Bharathi, Alexandre Bazinet, Alex Bataller, Naval Daver, Courtney DiNardo, Hussein Abbas, Ian Bouligny, Gautam Borthakur, Fadi Haddad, Naveen Pemmaraju, Steven Kornblau, Wei-Ying Jen, Nicholas Short, Andres Quesada, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2025-3405

Published: 2025

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Sankalp Arora, Jayastu Senapati, Nicholas Short, Musa Yilmaz, Sanam Loghavi, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Joseph Jabbour, Hannah Goulart, Ghayas Issa, Naveen Pemmaraju, Wei-Ying Jen, Hussein Abbas, Michael Andreeff, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2025-3397

Published: 2025

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Naveen Pemmaraju, Luca Mazzarella, Giovanni Marconi, David Sallman, Matthew Ulrickson, Roland Walter, Valerio Maisano, Breanne Fishman, Yining Du, Jalaja Potluri, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2025-5195

Published: 2025

Journal Articles

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sanam Loghavi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Jayastu Senapati, Wei-Ying Jen, Naveen Pemmaraju, Fnu Amritpal Singh, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2025-5179

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Roberta S. Azevedo, Guillermo Garcia-Manero, Elias Jabbour, Danielle Hammond, Kelly Chien, Tapan Kadia, Steven Kornblau, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Hyunsoo Hwang, Xuelin Huang, Heather Schneider, Meghan Meyer, Guillermo Montalban-Bravo

Blood (2025) 146 (Supplement 1): 5645.

https://doi.org/10.1182/blood-2025-5645

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2025-3849

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database

Naveen Pemmaraju, Alexis Garduno, Jennifer Repp, Shayna Adams, Taylor Schwartz, Ahmad Naim, Valkal Bhatt, Jingbo Yu

Blood (2025) 146 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2025-2826

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Blood (2025) 146 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2025-2053

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only